Online citations, reference lists, and bibliographies.
← Back to Search

Nanosizing: A Formulation Approach For Poorly-water-soluble Compounds.

E. Merisko-Liversidge, G. Liversidge, E. Cooper
Published 2003 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Poorly-water-soluble compounds are difficult to develop as drug products using conventional formulation techniques and are frequently abandoned early in discovery. The use of media milling technology to formulate poorly-water-soluble drugs as nanocrystalline particles offers the opportunity to address many of the deficiencies associated with this class of molecules. NanoCrystal Technology is an attrition process wherein large micron size drug crystals are media milled in a water-based stabilizer solution. The process generates physically stable dispersions consisting of nanometer-sized drug crystals. Nanocrystalline particles are a suitable delivery system for all commonly used routes of administration, i.e. oral, injectable (IV, SC, and IM) and topical applications. In addition, aqueous dispersions of nanoparticles can be post-processed into tablets, capsules, fast-melts and lyophilized for sterile product applications. The technology has been successfully incorporated into all phases of the drug development cycle from identification of new chemical entities to refurbishing marketed products for improving their performance and value.
This paper references
10.1016/S0169-409X(00)00096-X
Places of emulsions in drug delivery.
M. Nakano (2000)
Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size.
G. Kong (2000)
10.1016/j.addr.2012.09.018
Microemulsion-based media as novel drug delivery systems.
M. Lawrence (2000)
10.1016/0169-409X(90)90017-M
Nanoparticles as microcarriers for anticancer drugs
P. Couvreur (1990)
10.1016/S0939-6411(02)00061-9
Melt extrusion: from process to drug delivery technology.
J. Breitenbach (2002)
10.1111/j.1349-7006.1998.tb00563.x
Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues
Youichiro Noguchi (1998)
10.1023/A:1012024021511
Nebulization of NanoCrystals™: Production of a Respirable Solid-in-Liquid-in-Air Colloidal Dispersion
T. Wiedmann (2004)
10.1016/0378-5173(95)00148-C
Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats
G. Liversidge (1995)
10.3109/03639049709150497
Sterile Filtration of NanoCrystal™ Drug Formulations
Jane Zheng (1997)
Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro.
F. Martin (1982)
10.1016/s0169-409x(96)00423-1
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
C. Lipinski (2001)
Pharmacokinetics and hepatic disposition of bis[1-(ethoxycarbonyl)propyl]5-acetylamino-2,4,6-triiodoisophthalate in rats and isolated perfused rat livers.
Y. Liu (2000)
10.1023/A:1016051316815
Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs
E. Merisko-Liversidge (2004)
Nanoparticles in drug delivery.
S. J. Douglas (1987)
10.1016/S0168-3659(00)00269-8
Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro.
C. E. Soma (2000)
10.1016/S1461-5347(99)00141-8
Top ten considerations in the development of parenteral emulsions.
Floyd (1999)
Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters.
B. Bittner (2002)
10.1023/A:1018883431970
Physical Stability of Ethyl Diatrizoate Nanocrystalline Suspension in Steam Sterilization
G. Na (2004)
10.1126/science.271.5252.1079
Delivery of Molecular Medicine to Solid Tumors
R. Jain (1996)
10.1021/JS950534B
Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.
T. Loftsson (1996)
10.1016/S0939-6411(00)00076-X
Improving drug solubility for oral delivery using solid dispersions.
C. Leuner (2000)
Handbook of Pharmaceutical Excipients
A. H. Kibbe (2003)
10.1073/PNAS.95.8.4607
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
S. Hobbs (1998)
10.1002/jps.2600650641
Remington's pharmaceutical sciences
J. P. Remington (1985)
10.1016/0378-5173(95)00122-Y
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
G. Liversidge (1995)
10.1016/S0169-409X(97)00136-1
Controlling liposome blood clearance by surface-grafted polymers.
Woodle (1998)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1016/0021-8502(91)90013-8
Particle formation with supercritical fluids—a review
J. Tom (1991)
10.1016/0169-409X(88)90004-X
Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions
R. Juliano (1988)
10.1023/A:1016241927429
Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations
S. Byrn (2004)
10.2165/00003495-199700544-00004
Liposomes. Opportunities in drug delivery.
T. Allen (1997)
Poor aqueous solubility-an industry wide problem in drug discovery
C. Lipinski (2002)
10.1002/JPS.10154
Excipient-drug interactions in parenteral formulations.
M. Akers (2002)
10.1023/A:1011984216775
Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
J. Dressman (2004)
10.1016/S0169-409X(00)00118-6
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)
10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G
Bioadhesive-based dosage forms: the next generation.
J. W. Lee (2000)
10.1126/SCIENCE.8128245
Biodegradable long-circulating polymeric nanospheres.
R. Gref (1994)
10.1016/0378-5173(90)90047-8
Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants
S. Tröster (1990)
10.1016/0169-409X(95)00025-3
Long circulating microparticulate drug carriers
S. Stolnik (1995)
10.1016/S0169-409X(96)00487-5
Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract.
D. Hörter (1997)
10.1023/A:1012136608249
Cyclodextrins: Their Future in Drug Formulation and Delivery
V. Stella (2004)
10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6
Role of the development scientist in compound lead selection and optimization.
S. Venkatesh (2000)
10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
Intestinal permeation enhancers.
B. Aungst (2000)
10.1016/0024-3205(92)90073-X
Tumoricidal activity of Kupffer cells augmented by anticancer drugs.
Y. Adachi (1992)
10.1016/S0168-3659(99)00034-6
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.
L. Benet (1999)
10.1021/JS980403L
Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs.
A. T. Serajuddin (1999)
10.1021/JS970100B
The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs.
H. Kusuhara (1998)
10.1016/S0169-409X(00)00130-7
Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract.
D. Hörter (2001)
10.1023/A:1011987206722
Modification of the Copolymers Poloxamer 407 and Poloxamine 908 can Affect the Physical and Biological Properties of Surface Modified Nanospheres
J. Neal (2004)
10.1021/JM020017N
Molecular properties that influence the oral bioavailability of drug candidates.
D. Veber (2002)
10.1016/0378-5173(82)90113-2
Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape
L. Ilium (1982)
10.1081/DDC-100108363
Solution-Based Particle Formation of Pharmaceutical Powders by Supercritical or Compressed Fluid Co2 and Cryogenic Spray-Freezing Technologies
T. L. Rogers (2001)
10.1016/S0167-7799(00)89017-4
Engineering liposomes for drug delivery: progress and problems.
G. Gregoriadis (1995)
10.1016/S0169-409X(97)00135-X
Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions.
Papisov (1998)



This paper is referenced by
10.3390/pharmaceutics2040339
Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids
S. Mirza (2010)
10.7282/T31G0KBR
NUMERICAL AND EXPERIMENTAL ANALYSIS OF BREAKAGE IN A MILL USING THE ATTAINABLE REGION APPROACH
Matthew J. Metzger (2011)
10.1517/17425240903307423
Recent advances in intravenous delivery of poorly water-soluble compounds
Y. Shi (2009)
10.4155/TDE.10.4
Nanoparticulate strategies for effective delivery of poorly soluble therapeutics.
E. Gokce (2010)
Improving celecoxib bioavailability with β-casein nanocarriers
(2013)
10.19080/mabb.2017.03.555602
Nanoparticles Using as Efficient Bioavailability in Drug Delivery System-Mini Review
Md. Shahed-Al-Mahmud (2018)
NANOPARTICLE TECHNOLOGY: FORMULATING POORLY WATER-SOLUBLE COMPOUNDS: A REVIEW
Renu Sharma (2014)
10.2147/ijn.s41619
Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica [Erratum]
Zhouhua Wang (2013)
10.1002/jps.21380
Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies.
J. Z. Yang (2008)
10.1016/j.ejpb.2010.05.009
Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Y. Shono (2010)
10.1007/s11095-011-0465-y
Design of Dry Nanosuspension with Highly Spontaneous Dispersible Characteristics to Develop Solubilized Formulation for Poorly Water-Soluble Drugs
T. Niwa (2011)
10.1016/J.EJPB.2007.02.008
A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound.
K. Sigfridsson (2007)
DRUG NANOCRYSTALS: A NOVEL FORMULATION APPROACH FOR POORLY SOLUBLE DRUGS
Suman Katteboinaa (2009)
10.1007/S00339-010-5814-X
Laser fragmentation of organic microparticles into colloidal nanoparticles in a free liquid jet
Philipp Wagener (2010)
10.1128/AAC.00630-06
Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation
J. Mouton (2006)
10.1021/mp4003706
Dissolution enhancement of itraconazole by hot-melt extrusion alone and the combination of hot-melt extrusion and rapid freezing--effect of formulation and processing variables.
B. Lang (2014)
10.3109/9781420020298-6
Approaches for Improving Bioavailability of Poorly Soluble Drugs
N. Shah (2008)
10.1016/S1369-7021(05)71034-8
Targeted cancer nanotherapy
Gloria J. Kim (2005)
10.1208/s12249-011-9651-9
Formulation and Stability Testing of Itraconazole Crystalline Nanoparticles
A. Badawi (2011)
10.1007/978-1-4419-1087-5_5
Preclinical Development for Suspensions
S. Garad (2010)
10.1080/17425247.2019.1588248
Development and evaluation of intramuscularly administered nano/microcrystal suspension
Ziwei Ma (2019)
10.3109/03639045.2012.676048
Continuous production of drug nanoparticle suspensions via wet stirred media milling: a fresh look at the Rehbinder effect
A. Monteiro (2013)
10.1248/BPB.B12-00273
Development of a novel and customizable two-solution mixing type spray nozzle for one-step preparation of nanoparticle-containing microparticles.
T. Ozeki (2012)
10.1016/j.ijpharm.2015.07.057
Dry state microcrystals stabilized by an HPMC film to improve the bioavailability of andrographolide.
Y. Zhang (2015)
10.1016/j.ejpb.2019.05.024
Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.
D. Pade (2019)
10.2174/0929867325666181101110050
Nanocarriers: A Successful Tool to Increase Solubility, Stability and Optimise Bioefficacy of Natural Constituents.
A. Bilia (2018)
10.1007/s13346-018-0576-7
In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions—a metabolic approach
L. D. Silva (2018)
10.1016/j.ejpb.2015.11.011
Effect of polymer species and concentration on the production of mefenamic acid nanoparticles by media milling.
Atsutoshi Ito (2016)
10.1007/S12247-020-09499-1
Nanocrystals: Characterization Overview, Applications in Drug Delivery, and Their Toxicity Concerns
M. Jahangir (2020)
10.1016/J.FOODHYD.2017.10.019
Fabrication of milled cellulose particles-stabilized Pickering emulsions
Xuanxuan Lu (2017)
10.1002/mabi.201600228
Layer-by-Layer Coating of Solid Drug Cores: A Versatile Method to Improve Stability, Control Release and Tune Surface Properties.
Anna K Polomska (2017)
10.1016/j.ijpharm.2013.12.039
Quality by Design approach to spray drying processing of crystalline nanosuspensions.
S Kumar (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar